Date: 2017-08-07
Type of information: Fundraising
Company: Cuorips (Japan)
Investors: Daiichi Sankyo (Japan)
Amount:
Funding type: investment
Planned used: Cuorips is a new company established in March 2017. This Osaka University spin-off is dedicated to the development and commercialization of iPS-derived cardiomyocyte (iPS-CM) sheet based on the research data and technologies developed by the university. The iPS-CM sheet is an allogeneic cell therapy product consisting of cardiomyocyte derived from human iPS cells. Its transplantation is expected to provide improvement of cardiac function and amelioration of heart failure and become a new treatment option for patients with severe heart failure, who have no remedies other than heart transplantation or artificial heart implantation.
Others: • On August 7, 2017, Daiichi-Sankyo announced that it has signed an investment contract with Cuorips, an Osaka University spin-off venture to receive an option right concerning the worldwide commercialization of iPS-derived cardiomyocyte. Daiichi Sankyo Group has been conducting research on iPS cell-derived cardiomyocyte and their production, and is currently working on the efficient production process capable for commercial supply. Daiichi Sankyo and Cuorips are aiming to commercialize iPS-CM sheets as a pioneering treatment for severe heart failure.
Therapeutic area:
